A phase I study of Anti-CD38 CAR-T cell therapy
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Anti-CD38 CAR-T Cells-Sorrento Therapeutics (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- 28 Mar 2018 According to a Sorrento Therapeutics media release, the company expects to initiate this trial in 1H 2018.
- 15 Dec 2016 New trial record
- 01 Dec 2016 According to a Sorrento Therapeutics media release, the company plans to file an Investigational New Drug Application (IND) in the first half of 2017 and trial initiation is expected in the second half of 2017.